Human TREM2 ELISA Kit

Protocol Booklet

Key features and details

Specification: 96 Test
Sensitivity: 0.004 ng/ml (50 μl)；0.05 ng/ml (50 μl)；
Standard Curve Range: 0.14~100 ng/ml
Standard Curve Gradient: 7 Points/3 Folds
Number of Incubations: 2
Sample Volume: 50 μl/10 μl
Assay type: Sandwich Elisa
Operation Duration: 75min

Brand:

CAT.NO. : AEHY0009

RMB Please choose

Size:

96T

Trail, Bulk size or Custom requests Please contact us

*产品价格可能会有所调整，请以品牌方官网实时更新的价格为准，以确保准确性。

Product Details

Background

TREM2 (Triggering Receptor Expressed by Myeloid cells) is an Ig superfamily cell surface receptor that activates a number of myeloid cell types. It is a member of a small gene family located on human chromosome 6p21 and mouse chromosome 17 in a region linked to the MHC. A single human TREM2 gene has been described, however, two closely related orthologs were reported in mouse. The proteins differ by only three amino acids and were designated TREM2a and TREM2b. TREM2 is type I transmembrane protein consisting of a single extracellular immunoglobulin (V-like) domain, a transmembrane domain with a positively charged lysine residue, and a short cytoplasmic tail. It associates with the signal adapter protein, DAP12, for signaling and function. DAP12 has a cytoplasmic ITAM that is phosphorylated upon ligand binding leading to the subsequent activation of cytoplasmic tyrosine kinases. TREM2 is expressed by immature monocyte-derived dendritic cells (DC), and expression is down-regulated upon activation of DC by microbial products and costimulatory signals. Ligation of TREM2 on immature DC with anti-TREM2 antibodies results in partial DC activation and the up-regulation of CCR7 and some co-stimulatory molecules. A role for TREM2 in the functioning of osteoclasts and microglia is suggested by the discovery that homozygous loss-of-function mutations in either TREM2 or DAP12 result in Nasu-Hakola disease characterized by a combination of presenile demetia and bone cysts. In vitro studies indicate that the differentiation of myeloid precursors into osteoclasts is dramatically impaired in TREM2 deficient individuals.

Typical data

ng/ml	O.D.		Average	Corrected
0.00	0.0061	0.0054	0.0058
0.14	0.0116	0.0115	0.0116	0.0058
0.41	0.0267	0.0281	0.0274	0.0217
1.23	0.0789	0.0792	0.0791	0.0733
3.70	0.2296	0.2361	0.2329	0.2271
11.11	0.6794	0.6593	0.6694	0.6636
33.33	1.7740	1.7290	1.7515	1.7458
100.00	3.3700	3.3340	3.3520	3.3463

Precision

	Intra-assay Precision			Inter-assay Precision
Sample Number	S1	S2	S3	S1	S2	S3
Sample Number	22	22	22	6	6	6
Average（ng/ml）	1.9	10.3	35.3	2.0	10.0	32.2
Standard deviation	0.1	0.4	1.8	0.1	0.5	1.9
Coefficient of variation（%）	2.8	3.6	5.1	4.1	4.9	5.9

Intra-assay Precision (Precision within an assay) Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-assay Precision (Precision between assays)Three samples of known concentration were tested six times on one plate to assess intra-assay precision.

Spike Recovery

The spike recovery was evaluated by spiking 3 levels of Human TREM2 into health human serum sample. The un-spiked serum was used as blank in this experiment.

The recovery ranged from 95% to 105% with an overall mean recovery of 101%.

Sample Values

Sample Matrix

Sample Evaluated

Range (ng/ml)

Detectable

Mean of Detectable (ng/ml)

Serum

1.20-4.84

100.0%

2.69

Serum/Plasma - Thirty samples from apparently healthy volunteers were evaluated for the presence of Human TREM2 in this assay.